Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM. Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study. The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as: * a shot under the skin at the study clinic * through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects. Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits). The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Elranatamab
- DRUG Pomalidomide
- DRUG Bortezomib
- DRUG Elotuzumab
Study Locations (20)
California
- Beverly Hills Cancer Center — Beverly Hills
- Community Cancer Institute — Clovis
- Clinical Research Advisors (Encino Satellite Location) — Encino
- Hoag Health Center Irvine — Irvine
- Hoag Hospital Irvine — Irvine
- Clinical Research Advisors (Korea Town Satellite Location) — Los Angeles
- Clinical Research Advisors (West Hollywood Satellite Location) — Los Angeles
- Valkyrie Clinical Trials — Los Angeles
- Hoag Memorial Hospital Presbyterian — Newport Beach
- Mission Community Hospital (Satellite Site) — Panorama City
- University of California Davis (UC Davis) Comprehensive Cancer Center — Sacramento
- University of California — Sacramento
Colorado
- UCHealth Poudre Valley Hospital — Fort Collins
- UCHealth Harmony — Fort Collins
- UCHealth Greeley Hospital — Greeley
- UCHealth Longs Peak Hospital — Longmont
- UCHealth Longs Peak Medical Center — Longmont
- UCHealth - Medical Center of the Rockies — Loveland
Alabama
- Infirmary Cancer Care — Mobile
Arizona
- Western Regional Medical Center, Inc. dba. City of Hope Phoenix — Goodyear
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 492 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06152575
The ClinicalTrials.gov registry entry for NCT06152575 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 492 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions — of which Dexamethasone is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06152575 reports 20 study locations spanning 4 distinct geographic areas — top geographies include California, Colorado, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06152575 about?
NCT06152575 is a clinical study titled "MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)". The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments bef...
What is the current status of trial NCT06152575?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 492 participants. The study started on 2024-02-08. Estimated completion is 2027-12-30.
What conditions does trial NCT06152575 study?
This clinical trial studies the following conditions: Multiple Myeloma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06152575?
The interventions under investigation include: Dexamethasone (DRUG), Elranatamab (DRUG), Pomalidomide (DRUG), Bortezomib (DRUG), Elotuzumab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06152575?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06152575 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.